Short Interest in Jaguar Animal Health, Inc. (NASDAQ:JAGX) Grows By 68.6%

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 87,153 shares, an increase of 68.6% from the July 15th total of 51,687 shares. Approximately 14.5% of the company’s stock are sold short. Based on an average daily volume of 119,074 shares, the days-to-cover ratio is presently 0.7 days.

Jaguar Animal Health Stock Performance

JAGX traded up $0.09 during trading hours on Tuesday, reaching $0.96. The company’s stock had a trading volume of 60,307 shares, compared to its average volume of 105,282. The company’s 50-day moving average is $1.86 and its 200-day moving average is $9.67. Jaguar Animal Health has a 52 week low of $0.72 and a 52 week high of $85.40. The firm has a market cap of $581,895.00, a PE ratio of -0.00 and a beta of -0.06.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings data on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, topping analysts’ consensus estimates of ($149.10) by $135.50. The company had revenue of $20.27 million for the quarter, compared to the consensus estimate of $4.21 million.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JAGX. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.